Report Publication Announcement • Jul 31, 2025
Report Publication Announcement
Open in ViewerOpens in native device viewer
Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.
This document may be found on the company's corporate website: www.sanofi.com and downloaded from the "Investors" page, under the heading "Regulated Information".
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply ourdeep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Léo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Victor Rouault | + 33 6 70 93 71 40 | [email protected]
Thomas Kudsk Larsen |+ 44 7545 513 693 | [email protected] Alizé Kaisserian | + 33 6 47 04 12 11 | [email protected] Felix Lauscher| + 1 908 612 7239 | [email protected] Keita Browne| + 1 781 249 1766 | [email protected] Nathalie Pham| + 33 7 85 93 30 17 | [email protected] Tarik Elgoutni | + 1 617 710 3587 | [email protected] Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.